drugset / Trial / NCT06421675
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2
Recruiting
40 enrolled
Ontario Clinical Oncology Group (OCOG)
McMaster University · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Timeline
- Start
- 2025-03-28
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | 76 mg | Subcutaneous |